Cathy Bull

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

Ningshu Liu, Bruce R. Rowley, Cathy Bull et al. · Molecular Cancer Therapeutics · 2013 · 251 citations

Molecular Pharmacology, Tumor Biology, Pi3k Inhibitors +15

Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐<i>c</i>]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)

William J. Scott, Martin Hentemann, R. Rowley et al. · ChemMedChem · 2016 · 111 citations · Full text

Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor

Jean‐Marc Lapierre, Sudharshan Eathiraj, David Vensel et al. · Journal of Medicinal Chemistry · 2016 · 105 citations · Full text

Pharmaceutical Science, Pharmacotherapy, Pharmaceutical Chemistry +18

Discovery and Optimization of a Series of 3-(3-Phenyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors

Mark A. Ashwell, Jean‐Marc Lapierre, Christopher J. Brassard et al. · Journal of Medicinal Chemistry · 2012 · 98 citations · Full text

Chemical Biology, Pharmaceutical Chemistry, Biophysical Screening Strategy +19

Gender and developmental patterns of affect, belief, and behavior in simulated injury events

Lizette Peterson, Tammy J. Brazeal, Krista K. Oliver et al. · Journal of Applied Developmental Psychology · 1997 · 38 citations

Simulated Injury Events, Gendered Perception, Behavioral Sciences +13